1️⃣ ADMA widened ASCENIV below adolescence
FDA expanded ASCENIV’s primary humoral immunodeficiency label to patients aged 2 and older. The product was previously limited to patients aged 12 and older.
💡 Why it matters
This is not a new asset, but it widens a commercial plasma-derived biologic into younger PI patients and cleans up a pediatric post-marketing commitment.
☕ Coffee talk
How much more room does ADMA get from label work before this becomes mostly a manufacturing story?
2️⃣ Gyre closed the Cullgen reset
Gyre completed its all-stock acquisition of Cullgen, valued at about $300M, adding targeted protein degrader and degrader-antibody conjugate programs to a fibrosis-first company.
💡 Why it matters
The deal turns Gyre into a U.S.-China platform story with China commercial revenue, a late-stage fibrosis asset and a broader degrader pipeline.
☕ Coffee talk
Is this enough platform density, or just a small public company buying a second narrative?
3️⃣ Garda kept Assertio moving, just later
Assertio and Garda pushed the tender-offer start to May 8 under Garda’s amended all-cash deal to buy Assertio for $21.80 per share, or $153.2M.
💡 Why it matters
The economics did not change. The signal is process discipline in a small specialty-pharma takeout where the tender and notes offers now move together.
☕ Coffee talk
If the spread is already tight, what is left here for anyone except deal-arb desks?